Related Experiment Video

Updated: Feb 20, 2026

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
11:18

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Published on: May 7, 2012

13.4K

Expanding the use of hepatitis C-viremic kidney donors

Deirdre Sawinski1, Christina M Wyatt2, Jayme E Locke3

  • 1Department of Medicine, Renal, Electrolyte, and Hypertension Division, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.

Kidney International
|October 23, 2017
PubMed

Insights

Direct-acting antivirals offer new hope for hepatitis C virus (HCV) patients with chronic kidney disease. Expanding organ transplantation from HCV-positive donors to negative recipients shows promise but requires further research.

Area of Science:

  • Nephrology
  • Hepatology
  • Transplantation Immunology

Background:

  • Hepatitis C virus (HCV) infection poses challenges for patients with chronic kidney disease (CKD).
  • Direct-acting antivirals (DAAs) have transformed HCV treatment.
  • CKD patients and kidney transplant candidates require specific treatment considerations.

Purpose of the Study:

  • To review the safety and cost-effectiveness of using organs from HCV-viremic donors for HCV-negative recipients.
  • To discuss the implications of DAAs for HCV treatment timing in kidney transplant candidates.
  • To explore the broader impact on the organ transplantation community.

Main Methods:

  • Review of current literature and data on DAA efficacy and safety in CKD patients.
  • Analysis of consensus conference findings regarding HCV-positive donor organ utilization.
  • Evaluation of early trial results for expanded organ acceptance protocols.

Main Results:

  • DAAs have significantly improved HCV treatment outcomes.
  • Utilizing HCV-viremic donors for HCV-negative recipients is a promising strategy.
  • Early trials indicate potential safety and efficacy, but further investigation is warranted.

Conclusions:

  • Further large-scale trials are essential to validate the use of HCV-viremic organs.
  • A clear plan for post-transplantation HCV therapy is necessary.
  • The findings have significant implications for expanding the donor pool and improving outcomes in kidney transplantation.
Keywords:
direct-acting antiviralshepatitis c viruskidney transplantation

More Related Videos

Porcine Liver Transplantation Without Veno-Venous Bypass As an Extended Criteria Donor Model12:49

Porcine Liver Transplantation Without Veno-Venous Bypass As an Extended Criteria Donor Model

Published on: August 17, 2022

3.2K
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

10.0K

Related Concept Videos

Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
537
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
492
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
362
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
431
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
252